Baxter International, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0718131099
USD
18.48
-0.41 (-2.17%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Baxter International, Inc. stock-summary
stock-summary
Baxter International, Inc.
Pharmaceuticals & Biotechnology
Baxter International Inc., through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products. The Renal business offers a portfolio to meet the needs of patients with end-stage renal disease, or irreversible kidney disease and acute kidney injuries, including technologies and therapies for peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapy (CRRT) and additional dialysis services. Its products are used by hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices and by patients at home under physician supervision.
Company Coordinates stock-summary
Company Details
1 Baxter Pkwy , DEERFIELD IL : 60015-4625
stock-summary
Tel: 1 847 9482000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 144 Schemes (51.42%)

Foreign Institutions

Held by 363 Foreign Institutions (16.25%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Jose Almeida
Chairman of the Board, President, Chief Executive Officer
Mr. Thomas Stallkamp
Lead Independent Director
Mr. Thomas Chen
Independent Director
Mr. John Forsyth
Independent Director
Dr. James Gavin
Independent Director
Mr. Peter Hellman
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
2,810 Million
(Quarterly Results - Jun 2025)
Net Profit:
122 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 16,610 Million (Small Cap)

stock-summary
P/E

31.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.08%

stock-summary
Debt Equity

1.07

stock-summary
Return on Equity

7.91%

stock-summary
Price to Book

2.27